Jade Biosciences (JBIO) EBT (2020 - 2026)
Jade Biosciences' (JBIO) quarterly EBT came in at -$40.4 million in Q1 2026, down 5.72% YoY from -$42.8 million in Q1 2025, and down 15.36% on a QoQ basis from -$35.0 million in Q4 2025.
Jade Biosciences (JBIO) EBT (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of EBT data on file, last reported at -$40.4 million in Q1 2026.
- Quarterly EBT fell 5.72% year-over-year to -$40.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.0 million (down 58.35% YoY) and the FY2025 annual result came in at $236000.0, up 100.34% from the prior year.
- EBT fell to -$40.4 million in Q1 2026, from -$35.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$10.9 million in Q1 2022 to a low of -$118.1 million in Q1 2024.
- A 5-year average of -$43.4 million and a median of -$40.4 million in 2026 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT sank 452.25% — and 2025, when it soared 67.68%.
- Tracing JBIO's EBT over 5 years: stood at -$15.8 million in 2022, then slumped by 40.57% to -$22.2 million in 2023, then slumped by 111.76% to -$47.0 million in 2024, then advanced by 25.54% to -$35.0 million in 2025, then retreated by 15.36% to -$40.4 million in 2026.
- The last three EBT figures came in at -$40.4 million (Q1 2026), -$35.0 million (Q4 2025), and -$56.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | -55.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.75 Mn |
| Mar 31, 2026 | -40.35 Mn |
| Dec 31, 2025 | -34.98 Mn |
| Sep 30, 2025 | -56.71 Mn |
| Jun 30, 2025 | -70.00 Mn |
| Mar 31, 2025 | -38.17 Mn |
| Dec 31, 2024 | -46.98 Mn |
| Sep 30, 2024 | -15.57 Mn |
| Jun 30, 2024 | -26.88 Mn |
| Mar 31, 2024 | -118.08 Mn |
| Dec 31, 2023 | -22.19 Mn |
| Sep 30, 2023 | -39.12 Mn |
| Jun 30, 2023 | -50.25 Mn |
| Mar 31, 2023 | -60.25 Mn |
| Dec 31, 2022 | -15.78 Mn |
| Sep 30, 2022 | -48.30 Mn |
| Jun 30, 2022 | -43.85 Mn |
| Mar 31, 2022 | -10.91 Mn |
| Dec 31, 2021 | -8.27 Mn |
| Sep 30, 2021 | -48.64 Mn |